Total Utang marang Modal CytoMed Therapeutics (GDTC)
CytoMed Therapeutics (GDTC) relies on a strong talent pool of immunologists and clinical research experts in Southeast Asia. This business is resilient to market downturns, as oncology remains a top priority. The historical debt-to-equity ratio stands at 0.09, linking the financial profile to the development of off-the-shelf NK-cell therapies that mitigate risks through mass application.
%20-%20Total%20Utang%20marang%20Modal&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_GDTC_-_CytoMed-Therapeutics_-_Total-Debt-to-Capital "Utang marang Ekuitas CytoMed Therapeutics (GDTC): kanggo periode 21.02.2024 - 29.10.2026 | 👁️GURU.Markets👁️")
Rincian metrik lan analitis perusahaan CytoMed Therapeutics Limited (GDTC)
- rega saham lan konsensus proyeksi valuasi:
- rincian kapitalisasi pasar:
- indikator kapitalisasi buku:
- rincian utang lan likuiditas:
Total Utang marang Modal CytoMed Therapeutics|GDTC - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas CytoMed Therapeutics Ltd|GDTC - Kewajiban utang agregat|Utang marang nilai buku CytoMed Therapeutics|GDTC - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan CytoMed Therapeutics|Indikator likuiditas cepet w2.cytomed.sg
- data bathi resik lan rasio valuasi:
Pambiji fundamental perusahaan:CytoMed Therapeutics
Analyzing the debt-to-equity ratio of CytoMed Therapeutics (GDTC) allows for an assessment of the biotech startup's financial stability during the development stage of gamma-delta T-cell therapies. This metric compares total liabilities to equity, where a market revaluation of assets following successful clinical trials reduces credit risk, confirming the company's ability to fund innovation without excessive debt leverage.
Analisis pesaing CytoMed Therapeutics
ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Total Utang marang Modal CSBR|Rasio Total Utang marang Ekuitas xbiotech.com XBIT|CEL-SCI - Rasio Total Utang marang Ekuitas|OS Therapies Inc. (OSTX) - Utang marang Modal|RADX: Rasio Total Utang marang Ekuitas|Artiva Biotherapeutics, Inc. - Utang Agregat marang Modal|adlainortye.com (ANL) - Utang marang Ekuitas|Utang marang Modal verupharma.com (VERU)|Utang marang Ekuitas Tempest Therapeutics, Inc.|Rasio Total Utang marang Ekuitas Xilio (XLO)|Total Utang marang Modal RENB|MURA - Utang marang Modal|Total Utang marang Modal KAPA (Kairos Pharma)|OKUR: Rasio Utang marang Ekuitas|CRIS: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi APLM (Apollomics, Inc.)|THAR (Tharimmune Corp) - Rasio Total Utang marang Ekuitas|ADVB: Utang Agregat marang Modal|GNPX (Genprex, Inc.) - Total Utang marang Modal|CLDI: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SBFM|XBIO - Utang marang Modal|Utang marang Ekuitas Salarius SLRX|Rasio Kabeh Utang marang Dana Pribadi PPBT|AON - Total Utang marang Modal|BGNE - Total Utang marang Modal|Checkpoint Therapeutics, Inc. (CKPT) - Utang marang Ekuitas|Utang Agregat marang Ekuitas ELEV (elevationoncology.com)|ICAD (iCAD Inc.) - Total Utang marang Modal|Utang marang Modal Ikena IKNA|Rasio Total Utang marang Ekuitas NTBL (Notable Labs, Ltd.)|Total Utang marang Modal viracta.com (VIRX)|MorphoSys - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal NAYA (NAYA Biosciences Inc)|Ascentage Pharma Group Ltd - Total Utang marang Modal